KalshiFerméVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesAssez bien calibréCe marché est fermé et en attente d'une résolution confirmée.
En attente d'une résolution vérifiée
CoinRithm attend un règlement confirmé par le fournisseur avant de traiter ce marché comme résolu.
Probabilité implicite actuelle
Before 2027 35%En tête parmi 3 options
Qualité du marché
35 / 100
Faible qualitéVolume 24h
—
Liquidité
29,7 k €
Liquidité élevéeDonnées du marché
Mis à jour il y a 9 minutes
24 mars 26, 14:00 UTC1 sept. 26, 03:59 UTC
Tendances
35%
20%
2%
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
FDA moves BPC-157 to Category 1 by which date?
PolymarketHantavirus pandemic in 2026?
PolymarketWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiWill we get AGI before 2027?
Manifold MarketsFDA approves skin cancer vaccine by which date?
PolymarketMeasles cases in 2026?
KalshiRègles
If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.
Règlement via:Food and Drug Administration
- The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
- Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Nov 1, 2026, then the market resolves to Yes.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes.
Marchés ouverts
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Volume total
- 15,6 M €
- Volume 24h
- 18 k €
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Volume total
- 920,1 k €
- Volume 24h
- 4 k €
KALSHIMedtronic cardiovascular growth in Q2
- Above 8%92%
- Above 9%81%
- Above 11.5%53%
+6 résultats de plus
- Volume total
- 2,6 k €
- Volume 24h
- 2,6 k €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000+1.0pt98%
- Above 6000+2.0pt61%
+2 résultats de plus
- Volume total
- 868,1 k €
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 résultats de plus
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Volume total
- 612,7 k €
- Volume 24h
- 1,2 k €
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Which countries will report an Ebola disease case before October?
- What will RFK say during RNC Midterm Convention?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will the FDA approve retatrutide?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Measles cases in U.S. by September 30?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- How many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
Questions fréquentes
- Quelles sont les probabilités actuelles pour When will the FDA reclassify BPC-157 to Category 1? ?
- Kalshi cote Before 2027 à 35% au 10 septembre 2026.
- Quand When will the FDA reclassify BPC-157 to Category 1? sera-t-il résolu ?
- When will the FDA reclassify BPC-157 to Category 1? doit être résolu le 1 septembre 2026.
- Comment When will the FDA reclassify BPC-157 to Category 1? est-il réglé ?
- Kalshi règle ce marché comme suit : If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.